Key insights
- AbbVie reported strong Q1 earnings, beating expectations and raising full-year EPS guidance, driving shares higher. Growth in immunology and neuroscience portfolios offset flat oncology revenue. While the new EPS guidance midpoint is slightly below consensus, the overall positive results and raised outlook suggest continued strength in the healthcare sector, providing a modestly bullish signal for the broader market.
Investing.com -- AbbVie Inc. (NYSE: ABBV) reported first-quarter results that exceeded Wall Street expectations, sending shares higher in premarket trading.
Adjusted earnings per share came in at $2.65, beating the analyst consensus of $2.59 by $0.06. Revenue reached $15.0 billion, surpassing the estimate of $14.73 billion and representing a 12.4% increase from the prior year period.
The company's immunology portfolio drove growth, generating $7.29 billion in revenue, up 16.4% YoY. Skyrizi led the portfolio with $4.48 billion in sales, up 30.9%, while Rinvoq contributed $2.12 billion, up 23.3%. The neuroscience portfolio posted $2.88 billion in revenue, a 26.0% increase, with Vraylar generating $905 million and Botox Therapeutic reaching $1.01 billion. Shares rose 2.5% following the announcement.
"We are off to an excellent start in 2026, with first-quarter results exceeding our expectations," said Robert A. Michael, chairman and chief executive officer. "AbbVie's key growth drivers continue to deliver strong performance and support our enhanced full-year outlook."
AbbVie raised its full-year 2026 adjusted diluted EPS guidance to a range of $14.08 to $14.28, up from the previous range of $13.96 to $14.16. The midpoint of $14.18 falls slightly below the analyst consensus of $14.21. The guidance includes an unfavorable impact of $0.41 per share related to acquired IPR&D and milestones expense incurred in the first quarter.
The oncology portfolio generated $1.63 billion, essentially flat YoY, with Venclexta contributing $770 million and Imbruvica adding $556 million. The aesthetics portfolio posted $1.19 billion in revenue, up 7.6%, driven by Botox Cosmetic at $668 million and Juvederm at $232 million.